Search hospitals > Indiana > Indianapolis
Sidney and Lois Eskenazi Hospital
Claim this profileIndianapolis, Indiana 46202
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Human Immunodeficiency Virus Infection
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
218 reported clinical trials
22 medical researchers
Summary
Sidney and Lois Eskenazi Hospital is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Cancer, Breast Cancer, Human Immunodeficiency Virus Infection, Lung Cancer, Non-Small Cell Lung Cancer and other specialties. Sidney and Lois Eskenazi Hospital is involved with conducting 218 clinical trials across 418 conditions. There are 22 research doctors associated with this hospital, such as Kathy Miller, MD, Nabil Adra, MD, Shadia Jalal, MD, and Rafat Abonour, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
Top PIs
Kathy Miller, MDIndiana University/Melvin and Bren Simon Cancer Center8 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
17 reported clinical trials
55 drugs studied
Nabil Adra, MDIndiana University Melvin and Bren Simon Cancer Center4 years of reported clinical research
Studies Prostate Cancer
Studies Cancer
15 reported clinical trials
32 drugs studied
Shadia Jalal, MDIndiana University/Melvin and Bren Simon Cancer Center9 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
21 drugs studied
Rafat Abonour, MDIndiana University/Melvin and Bren Simon Cancer Center6 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
7 reported clinical trials
11 drugs studied
Clinical Trials running at Sidney and Lois Eskenazi Hospital
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Ovarian Cancer
Fallopian Tube Cancer
Cancer
Non-Hodgkin's Lymphoma
Laryngeal Cancer
Alzheimer's Disease
Peritoneal Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Sidney and Lois Eskenazi Hospital?
Sidney and Lois Eskenazi Hospital is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Cancer, Breast Cancer, Human Immunodeficiency Virus Infection, Lung Cancer, Non-Small Cell Lung Cancer and other specialties. Sidney and Lois Eskenazi Hospital is involved with conducting 218 clinical trials across 418 conditions. There are 22 research doctors associated with this hospital, such as Kathy Miller, MD, Nabil Adra, MD, Shadia Jalal, MD, and Rafat Abonour, MD.